A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has...
Vous n'êtes pas connecté
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukaemia, the approach has yet to realise its potential against paediatric solid tumours. Scientists at St. Jude Children’s Research Hospital have identified a way to improve CAR T–cell homing – a T cell’s ability [...]
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has...
June 27, 2025 -- The U.S. Food and Drug Administration announced today that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for...
New findings show that the stage of normal cell development at which B cells transform into leukemic cells affects treatment outcomes for paediatric...
Advanced treatments, known as immunotherapies that activate T cells—our body’s immune cells—to eliminate cancer cells, have shown limited...
In vivo CAR T cell generation is a pioneering immunotherapy approach that reprograms the immune system to fight cancer and autoimmune diseases.
Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have shown limited efficacy...
Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have shown limited efficacy...
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute, USA, report the identification of a novel combination therapy...
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute, USA, report the identification of a novel combination therapy...
Melanoma, one of the deadliest forms of skin cancer, affects an estimated 330,000 people worldwide each year and causes nearly 60,000 deaths...